We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01900665
Previous Study | Return to List | Next Study

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo (EXPEDITION 3)

This study has been terminated.
(Solanezumab did not meet the study's primary endpoint.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01900665
First Posted: July 16, 2013
Last Update Posted: March 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Eli Lilly and Company
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2017
  Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: December 21, 2016